Clinical Trials Logo

Liver Metastasis clinical trials

View clinical trials related to Liver Metastasis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03428477 Active, not recruiting - Colon Cancer Clinical Trials

EPA for Metastasis Trial 2

EMT2
Start date: May 2, 2018
Phase: Phase 3
Study type: Interventional

A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease. A previous small study (the EMT study) suggested a possible survival benefit in patients who took the naturally-occurring omega-3 fatty acid EPA (a fish oil supplement) before liver surgery. The EMT2 study is a larger study which will recruit 448 men and women with liver metastases from bowel cancer. Trial participants will receive either Icosapent Ethyl (pure EPA derived from fish oil) or placebo (dummy capsules). EMT2 will investigate whether patients who take this supplement before liver surgery and for up to four years after surgery, remain free of recurrence for longer than those who take placebo (dummy capsules)

NCT ID: NCT02597348 Active, not recruiting - Colorectal Cancer Clinical Trials

Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy

TRANSMET
Start date: February 2016
Phase: N/A
Study type: Interventional

This is a multicentric randomized parallel group open trial comparing 5-year survival of chemotherapy followed by LT (Group LT+C) versus chemotherapy alone (Group C) in patients with confirmed unresectable liver-only metastases, well controlled by chemotherapy (no progression) and extensively explored by modern imaging techniques. The primary objective of the trial is to validate in a large multicentric cohort of selected patients the possibility to obtain at least 50% 5-years survival with LT combined to chemotherapy compared to around 10% with chemotherapy alone.

NCT ID: NCT01347424 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography

Start date: January 2011
Phase: Phase 2
Study type: Interventional

Contrast enhancement ultrasonography(CEUS)could be used to evaluate the blood flow perfusion liver cancer. In this clinical trial, CEUS was used to evaluated the changes of blood flow perfusion of Secondary Malignant Neoplasm of Liver after treated with endostatin plus paclitaxel and carboplatin regimen.